AVITA Medical, Inc. (FRA:51KA)
2.920
-0.080 (-2.67%)
At close: Dec 4, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2017 - 2019 |
| Commercial | 64.02M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Commercial Growth | 28.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biomedical Advanced Research and Development Authority Revenue for Right of First Access | 195.00K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biomedical Advanced Research and Development Authority Revenue for Right of First Access Growth | -41.79% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Deferred Commercial | 33.00K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Deferred Commercial Growth | 0% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2017 - 2019 |
| United States | 62.16M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 34.08% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan | 1.43M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan Growth | -57.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Australia | 312.00K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Australia Growth | 40.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United Kingdom | 196.00K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United Kingdom Growth | 39.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| European Union | 155.00K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| European Union Growth | 203.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|